



2023年11月28日(火) 12:00

プログラム
配信開始予定
2024年3月28日まで掲載予定

日本の実臨床に即した視点で、ESMO Congress 2023の注目演題を解説する学会公式プログラム

先生方によるDiscussion動画を公開、解説演題のESMO発表スライドをDL可

JSMOがん薬物療法専門医の更新資格に必要な10単位を付与

※本コンテンツの閲覧には、登録によるアクセスキー発行(有料)が必須となります。お申し込み方法は以下をご覧ください。
JSMO会員またはESMO会員の方: 13,200円(税込) 非会員の方: 33,000円(税込)

閲覧方法

① トップページ (<https://www.bestofesmo.jp>) より
お申し込み・アクセスキー受領



※画面は2022年のものです。

② トップページ (<https://www.bestofesmo.jp>) より
アクセスキーにてログイン



※画面は2022年のものです。

トップページにはこちらの二次元コードからもアクセス可能です(10月24日告知サイト公開予定)。



▼ 以下の先生方による、各領域の解説動画、Discussion動画がご視聴可能です。▼

解説領域と先生方のご紹介(予定)

解説領域と先生方のご紹介(予定)	
Programme Chair	佐治 重衡 先生 (福島県立医科大学)
肺がん	大熊 裕介 先生 (司会: 国立がん研究センター中央病院) 赤松 弘朗 先生 (解説: 和歌山県立医科大学) 谷崎 潤子 先生 (解説: 近畿大学)
消化器がん	林 義人 先生 (司会: 大阪大学大学院) 小野澤 祐輔 先生 (司会: 静岡県立静岡がんセンター) 佐竹 悠良 先生 (解説: 高知大学) 大場 彬博 先生 (解説: 国立がん研究センター中央病院)
婦人科がん	野村 基雄 先生 (司会: 京都大学医学部附属病院) 松本 光史 先生 (解説: 兵庫県立がんセンター) 山本 香澄 先生 (解説: 兵庫県立がんセンター)
乳がん	小野 麻紀子 先生 (司会: がん研究会有明病院) 田辺 裕子 先生 (解説: 虎の門病院) 尾崎 由記範 先生 (解説: がん研究会有明病院)
泌尿器がん	前嶋 愛子 先生 (司会: 国立がん研究センター中央病院) 近藤 千紜 先生 (解説: 国立がん研究センター東病院) 三浦 裕司 先生 (解説: 虎の門病院)

解説演題一覧

肺がん

解説: 赤松 弘明 先生 (和歌山県立医科大学 呼吸器内科・腫瘍内科)
谷崎 潤子 先生 (近畿大学医学部 内科学教室腫瘍内科部門)

演題番号	演題	演者
LBA14	Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial	Byoung Chul Cho
LBA5	Amivantamab Plus Carboplatin/Pemetrexed vs Carboplatin/Pemetrexed as First line Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From PAPHILLON, a Randomized Phase 3 Global Study	Nicolas Girard
LBA66	Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: a phase III study (ACHILLES/TORG1834)	Satoru Miura
LBA65	KRYSTAL 7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation	Marina Garassino
LBA12	Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung01	Myung-Ju Ahn
LBA2	ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)	Ben Solomon

消化器がん

解説: 佐竹 悠良 先生 (高知大学医学部 腫瘍内科学講座)
大場 彬博 先生 (国立がん研究センター中央病院 肝胆臓内科)

演題番号	演題	演者
LBA10	CB300 - randomized phase 3 trial comparing in 2nd/3rd line KRAS G12C colorectal patients either panitumumab/sotorasib (at 240 or 960 mg) vs SOC (trifluridine/tipiracil or regorafenib)	Filippo Pietrantonio
LBA73	Pathological complete response to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy with or without durvalumab in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the phase 3, randomised, double-blind MATTERHORN study	Yelena Janjigian
LBA74	Pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant and adjuvant therapy in advanced gastric and gastroesophageal junction cancer: The Phase 3 KEYNOTE-585 study	Kohei Shitara
15110	Pembrolizumab plus Trastuzumab and Chemotherapy for HER2+ Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Survival results from the Phase 3, Randomized, Double-blind, Placebo-controlled KEYNOTE-811 Study	Yelena Janjigian
LBA76	The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBERG Trial).	Shigenori Kadowaki
LBA77	5-fluorouracil and oxaliplatin with or without docetaxel in first-line treatment of HER2 negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GASTFOX-PRODIGE 51): a randomized phase 3 trial	Aziz Zaanani
LBA83	Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in patients with borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial	Bas Groot Koerkamp
16160	Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicenter, randomized, open-label, three-arm, phase 2/3 trial	Akihiro Ohba

婦人科がん

解説: 松本 光史 先生 (兵庫県立がんセンター 腫瘍内科・遺伝診療科・外来化学療法センター)
山本 香澄 先生 (兵庫県立がんセンター 婦人科)

演題番号	演題	演者
LBA8	A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial	Mary McCormack
LBA9	innovaTV 301/ENGOT-cx12/GOG-3057: A Randomized, Open-Label, Phase 3 Study of Tisotumab Vedotin vs Investigator's Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer	Ignace Vergote
LBA38	ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer	Domenica Lorusso
LBA40	Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.	Nicoletta Colombo
LBA41	Durvalumab (durva) plus paclitaxel/carboplatin (PC) followed by maintenance durva with or without olaparib (ola) as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the Phase III DUO-E/GOG-3041/ENGOT-EN10 trial	Shannon Westin
740MO	Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/REC): analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial	Mansoor Raza Mirza

乳がん

解説: 田辺 裕子 先生 (虎の門病院 臨床腫瘍科)
尾崎 由記範 先生 (がん研究会有明病院 乳腺内科)

演題番号	演題	演者
LBA11	Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised Phase 3 TROPION-Breast01 trial.	Aditya Bardia
LBA18	Overall survival results from KEYNOTE-522: Pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early stage triple-negative breast cancer	Peter Schmid
LBA19	Event-free survival (EFS) analysis of the neoadjuvant treatment with or without atezolizumab in high-risk triple negative breast cancer (TNBC). NeoTRIP Michelangelo randomized study.	Luca Gianni
LBA20	7FL phase III study of neoadjuvant chemotherapy with nivolumab or placebo in high grade hormone positive early breast cancer	Sherene Loi
LBA21	Randomized phase 3 study of neoadjuvant chemotherapy (NAC) + pembrolizumab (pembro) vs placebo (pbo), followed by adjuvant endocrine treatment + pembro vs pbo for early stage high-risk ER+/HER2- breast cancer: KEYNOTE-756.	Fatima Cardoso
LBA23	Invasive disease-free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + endocrine therapy (ET) in patients (pts) with HR+/HER2- early breast cancer (EBC)	Aditya Bardia

泌尿器がん

解説: 近藤 千紘 先生 (国立がん研究センター東病院 腫瘍内科)
三浦 裕司 先生 (虎の門病院 臨床腫瘍科)

演題番号	演題	演者
LBA6	EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC)	Thomas B. Powle
LBA7	Nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results for cisplatin-eligible patients in the phase 3 CheckMate 901 trial substudy	Michiel van der Heijden
LBA102	Phase 2 THOR-2 Study: Results of Erdafitinib Versus Intravesical Chemotherapy in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) With Select Fibroblast Growth Factor Receptor Alterations (FGFRalt) Who Received Prior Bacillus Calmette-Guérin (BCG) Treatment	James Catto
LBA13	Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic advanced-resistant prostate cancer (PSMAfore)	Oliver Sartor
LBA88	Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase 3 LITESPARK-005 study	Laurence Albiges
1765O	Interim Results From a Phase 1 Study of AMG 509 (xalutamide), a STEAP1 x CD3 XmA2+1 Immune Therapy, in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)	William Kelly